Montserrat Torrebadell

This study identifies the pre-TCR as a target for immunotherapy in T-ALL, showing that anti-pre-TCR antibodies inhibit leukemia-initiating cell activity and tumor progression in xenograft models.

This paper develops and validates a dual-targeting CAR-T cell therapy for T-ALL that targets CCR9 and CD1a, showing improved efficacy and safety compared to single-targeting approaches.